Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine versus placebo in heart failure with preserved ejection fraction
NL-OMON41325Phase 2Active, not recruiting
- Sponsor
- Servier
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and chronic heart failure (CHF) comparing Ivabradine with Placebo (2 arms). Primary endpoints: E/e* ratio, 6-minute walk test and 1 more. Started Oct 2013; status: active, not recruiting.
02
Drugs
ivabradine
03
Conditions
heart failure with preserved ejection fraction (HFpEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON41325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41325.